Revolution Medicines Officer Sells Shares for Tax Withholding

Insider Filing Analysis: Revolution Medicines, Inc. (RVMD)

Executive Summary

On September 18, 2026, Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc., reported the sale of 1,774 shares of Common Stock executed on September 16, 2026. The sales generated aggregate gross proceeds of approximately $353,449.10 at an average weighted price of roughly $199.24 per share.

Transaction Details

• Tranche 1: 27 shares sold at a weighted average price of $195.0521 (range: $195.03 - $195.07).
• Tranche 2: 1,747 shares sold at $199.3032 per share.
• Aggregate Shares Sold: 1,774 shares.
• Post-Transaction Holdings: 42,116 shares directly owned, which includes 39,575 restricted stock units (RSUs).

Context and Significance

This transaction carries Low informational significance for investors due to the following factors:

1. Routine Tax Withholding: Footnote 1 specifies that these transactions were conducted under a Rule 10b5-1 instruction letter adopted on June 15, 2026, specifically to satisfy tax withholding obligations triggered by the vesting of restricted stock units.
2. Pre-Planned Execution: Because the trades were executed automatically via a pre-established 10b5-1 plan to satisfy statutory tax obligations, they do not reflect executive sentiment regarding the company's operational prospects or valuation.